1	Supportive	_	_	JJ	_	_	_	_	_
2	care	_	_	NN	_	_	_	_	_
3	at	_	_	IN	_	_	_	_	_
4	home	_	_	NN	_	_	_	_	_
5	with	_	_	IN	_	_	_	_	_
6	plenty	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	rest	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	drinking	_	_	VBG	_	_	_	_	_
11	plenty	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	fluids	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	using	_	_	VBG	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	pain	_	_	NN	_	_	_	_	_
18	reliever	_	_	NN	_	_	_	_	_
19	for	_	_	IN	_	_	_	_	_
20	aches	_	_	NNS	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	pains	_	_	NNS	_	_	_	_	_
23	is	_	_	VBZ	_	_	_	_	_
24	adequate	_	_	JJ	_	_	_	_	_
25	for	_	_	IN	_	_	_	_	_
26	recovery	_	_	NN	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	most	_	_	JJS	_	_	_	_	_
29	cases	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	non-	_	_	JJ	_	_	_	_	_
3	aspirin	_	_	NN	_	_	_	_	_
4	pain	_	_	NN	_	_	_	_	_
5	reliever	_	_	NN	_	_	_	_	_
6	should	_	_	MD	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	used	_	_	VBN	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	children	_	_	NNS	_	_	_	_	_
11	or	_	_	CC	_	_	_	_	_
12	adolescents	_	_	NNS	_	_	_	_	_
13	under	_	_	IN	_	_	_	_	_
14	age	_	_	NN	_	_	_	_	_
15	18	_	_	CD	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	public	_	_	NN	_	_	_	_	_
3	should	_	_	MD	_	_	_	_	_
4	be	_	_	VB	_	_	_	_	_
5	made	_	_	VBN	_	_	_	_	_
6	aware	_	_	JJ	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	there	_	_	EX	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	specific	_	_	JJ	_	_	_	_	_
11	groups	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	people	_	_	NNS	_	_	_	_	_
14	who	_	_	WP	_	_	_	_	_
15	appear	_	_	VBP	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	be	_	_	VB	_	_	_	_	_
18	at	_	_	IN	_	_	_	_	_
19	higher	_	_	JJR	_	_	_	_	_
20	risk	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	more	_	_	RBR	_	_	_	_	_
23	complicated	_	_	JJ	_	_	_	_	_
24	or	_	_	CC	_	_	_	_	_
25	severe	_	_	JJ	_	_	_	_	_
26	illness	_	_	NN	_	_	_	_	_
27	which	_	_	WDT	_	_	_	_	_
28	include	_	_	VBP	_	_	_	_	_
29	:	_	_	:	_	_	_	_	_
30	pregnant	_	_	JJ	_	_	_	_	_
31	women	_	_	NNS	_	_	_	_	_
32	;	_	_	:	_	_	_	_	_
33	infants	_	_	NNS	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	and	_	_	CC	_	_	_	_	_
36	young	_	_	JJ	_	_	_	_	_
37	children	_	_	NNS	_	_	_	_	_
38	particularly	_	_	RB	_	_	_	_	_
39	under	_	_	IN	_	_	_	_	_
40	age	_	_	NN	_	_	_	_	_
41	2	_	_	CD	_	_	_	_	_
42	;	_	_	:	_	_	_	_	_
43	people	_	_	NNS	_	_	_	_	_
44	of	_	_	IN	_	_	_	_	_
45	any	_	_	DT	_	_	_	_	_
46	age	_	_	NN	_	_	_	_	_
47	with	_	_	IN	_	_	_	_	_
48	certain	_	_	JJ	_	_	_	_	_
49	chronic	_	_	JJ	_	_	_	_	_
50	health	_	_	NN	_	_	_	_	_
51	conditions	_	_	NNS	_	_	_	_	_
52	(	_	_	-LRB-	_	_	_	_	_
53	including	_	_	VBG	_	_	_	_	_
54	asthma	_	_	NN	_	_	_	_	_
55	or	_	_	CC	_	_	_	_	_
56	lung	_	_	NN	_	_	_	_	_
57	disease	_	_	NN	_	_	_	_	_
58	,	_	_	,	_	_	_	_	_
59	heart	_	_	NN	_	_	_	_	_
60	disease	_	_	NN	_	_	_	_	_
61	,	_	_	,	_	_	_	_	_
62	diabetes	_	_	NNS	_	_	_	_	_
63	,	_	_	,	_	_	_	_	_
64	kidney	_	_	NN	_	_	_	_	_
65	disease	_	_	NN	_	_	_	_	_
66	or	_	_	CC	_	_	_	_	_
67	some	_	_	DT	_	_	_	_	_
68	neurological	_	_	JJ	_	_	_	_	_
69	conditions	_	_	NNS	_	_	_	_	_
70	)	_	_	-RRB-	_	_	_	_	_
71	;	_	_	:	_	_	_	_	_
72	people	_	_	NNS	_	_	_	_	_
73	with	_	_	IN	_	_	_	_	_
74	severely	_	_	RB	_	_	_	_	_
75	compromised	_	_	VBN	_	_	_	_	_
76	immune	_	_	JJ	_	_	_	_	_
77	systems	_	_	NNS	_	_	_	_	_
78	.	_	_	.	_	_	_	_	_


1	Currently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	people	_	_	NNS	_	_	_	_	_
4	age	_	_	VBP	_	_	_	_	_
5	65	_	_	CD	_	_	_	_	_
6	or	_	_	CC	_	_	_	_	_
7	older	_	_	JJR	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	least	_	_	RBS	_	_	_	_	_
11	likely	_	_	JJ	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	be	_	_	VB	_	_	_	_	_
14	infected	_	_	VBN	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	pandemic	_	_	JJ	_	_	_	_	_
18	influenza	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	but	_	_	CC	_	_	_	_	_
21	those	_	_	DT	_	_	_	_	_
22	who	_	_	WP	_	_	_	_	_
23	do	_	_	VBP	_	_	_	_	_
24	get	_	_	VB	_	_	_	_	_
25	sick	_	_	JJ	_	_	_	_	_
26	are	_	_	VBP	_	_	_	_	_
27	also	_	_	RB	_	_	_	_	_
28	at	_	_	IN	_	_	_	_	_
29	high	_	_	JJ	_	_	_	_	_
30	risk	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	developing	_	_	VBG	_	_	_	_	_
33	serious	_	_	JJ	_	_	_	_	_
34	complications	_	_	NNS	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	just	_	_	RB	_	_	_	_	_
37	as	_	_	IN	_	_	_	_	_
38	they	_	_	PRP	_	_	_	_	_
39	are	_	_	VBP	_	_	_	_	_
40	from	_	_	IN	_	_	_	_	_
41	seasonal	_	_	JJ	_	_	_	_	_
42	flu	_	_	NN	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	(	_	_	-LRB-	_	_	_	_	_
2	(	_	_	-LRB-	_	_	_	_	_
3	MM	_	_	NNP	_	_	_	_	_
4	)	_	_	-RRB-	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	Is	_	_	VBZ	_	_	_	_	_
7	it	_	_	PRP	_	_	_	_	_
8	known	_	_	VBN	_	_	_	_	_
9	when	_	_	WRB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	virus	_	_	NN	_	_	_	_	_
12	will	_	_	MD	_	_	_	_	_
13	become	_	_	VB	_	_	_	_	_
14	less	_	_	RBR	_	_	_	_	_
15	virulent	_	_	JJ	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	cease	_	_	VB	_	_	_	_	_
18	becoming	_	_	VBG	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	major	_	_	JJ	_	_	_	_	_
21	threat	_	_	NN	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	health	_	_	NN	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	so	_	_	RB	_	_	_	_	_
27	when	_	_	WRB	_	_	_	_	_
28	?	_	_	.	_	_	_	_	_


1	(	_	_	-LRB-	_	_	_	_	_
2	(	_	_	-LRB-	_	_	_	_	_
3	KM	_	_	NNP	_	_	_	_	_
4	)	_	_	-RRB-	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	It	_	_	PRP	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	impossible	_	_	JJ	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	predict	_	_	VB	_	_	_	_	_
11	when	_	_	WRB	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	pandemic	_	_	JJ	_	_	_	_	_
14	H1N1	_	_	NNP	_	_	_	_	_
15	virus	_	_	NN	_	_	_	_	_
16	will	_	_	MD	_	_	_	_	_
17	become	_	_	VB	_	_	_	_	_
18	less	_	_	RBR	_	_	_	_	_
19	virulent	_	_	JJ	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Diagram	_	_	NN	_	_	_	_	_
2	showing	_	_	VBG	_	_	_	_	_
3	antigenic	_	_	JJ	_	_	_	_	_
4	shift	_	_	NN	_	_	_	_	_
5	.	_	_	.	_	_	_	_	_


1	(	_	_	-LRB-	_	_	_	_	_
2	(	_	_	-LRB-	_	_	_	_	_
3	MM	_	_	NNP	_	_	_	_	_
4	)	_	_	-RRB-	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	Is	_	_	VBZ	_	_	_	_	_
7	there	_	_	EX	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	significant	_	_	JJ	_	_	_	_	_
10	risk	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	H1N1	_	_	NN	_	_	_	_	_
13	mutating	_	_	VBG	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	becoming	_	_	VBG	_	_	_	_	_
16	more	_	_	RBR	_	_	_	_	_
17	deadly	_	_	JJ	_	_	_	_	_
18	?	_	_	.	_	_	_	_	_


1	(	_	_	-LRB-	_	_	_	_	_
2	(	_	_	-LRB-	_	_	_	_	_
3	KM	_	_	NNP	_	_	_	_	_
4	)	_	_	-RRB-	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	Influenza	_	_	NN	_	_	_	_	_
7	viruses	_	_	NNS	_	_	_	_	_
8	constantly	_	_	RB	_	_	_	_	_
9	change	_	_	VBP	_	_	_	_	_
10	through	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	process	_	_	NN	_	_	_	_	_
13	called	_	_	VBN	_	_	_	_	_
14	antigenic	_	_	JJ	_	_	_	_	_
15	drift	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	All	_	_	DT	_	_	_	_	_
2	influenza	_	_	NN	_	_	_	_	_
3	viruses	_	_	NNS	_	_	_	_	_
4	undergo	_	_	VBP	_	_	_	_	_
5	this	_	_	DT	_	_	_	_	_
6	process	_	_	NN	_	_	_	_	_
7	but	_	_	CC	_	_	_	_	_
8	there	_	_	EX	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	no	_	_	DT	_	_	_	_	_
11	way	_	_	NN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	predict	_	_	VB	_	_	_	_	_
14	if	_	_	IN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	when	_	_	WRB	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	how	_	_	WRB	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	pandemic	_	_	JJ	_	_	_	_	_
21	H1N1	_	_	NNP	_	_	_	_	_
22	virus	_	_	NN	_	_	_	_	_
23	will	_	_	MD	_	_	_	_	_
24	shift	_	_	VB	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	(	_	_	-LRB-	_	_	_	_	_
2	(	_	_	-LRB-	_	_	_	_	_
3	MM	_	_	NN	_	_	_	_	_
4	)	_	_	-RRB-	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	Are	_	_	VBP	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	current	_	_	JJ	_	_	_	_	_
9	anti-flu	_	_	JJ	_	_	_	_	_
10	vaccines	_	_	NNS	_	_	_	_	_
11	effective	_	_	JJ	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	how	_	_	WRB	_	_	_	_	_
14	sufficient	_	_	JJ	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	current	_	_	JJ	_	_	_	_	_
18	supply	_	_	NN	_	_	_	_	_
19	?	_	_	.	_	_	_	_	_


1	Can	_	_	MD	_	_	_	_	_
2	you	_	_	PRP	_	_	_	_	_
3	explain	_	_	VB	_	_	_	_	_
4	how	_	_	WRB	_	_	_	_	_
5	these	_	_	DT	_	_	_	_	_
6	anti-virus	_	_	JJ	_	_	_	_	_
7	vaccine	_	_	NN	_	_	_	_	_
8	work	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	any	_	_	DT	_	_	_	_	_
11	possible	_	_	JJ	_	_	_	_	_
12	side	_	_	NN	_	_	_	_	_
13	effects	_	_	NNS	_	_	_	_	_
14	?	_	_	.	_	_	_	_	_


1	(	_	_	-LRB-	_	_	_	_	_
2	(	_	_	-LRB-	_	_	_	_	_
3	KM	_	_	NNP	_	_	_	_	_
4	)	_	_	-RRB-	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	The	_	_	DT	_	_	_	_	_
7	current	_	_	JJ	_	_	_	_	_
8	H1N1	_	_	NNP	_	_	_	_	_
9	vaccines	_	_	NNS	_	_	_	_	_
10	are	_	_	VBP	_	_	_	_	_
11	effective	_	_	JJ	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	supply	_	_	NN	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	sufficient	_	_	JJ	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	safety	_	_	NN	_	_	_	_	_
3	profile	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	H1N1	_	_	NNP	_	_	_	_	_
6	vaccines	_	_	NNS	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	very	_	_	RB	_	_	_	_	_
9	good	_	_	JJ	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	Outcomes	_	_	NNS	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	studies	_	_	NNS	_	_	_	_	_
4	completed	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	date	_	_	NN	_	_	_	_	_
7	indicate	_	_	VBP	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	pandemic	_	_	JJ	_	_	_	_	_
10	vaccines	_	_	NNS	_	_	_	_	_
11	have	_	_	VBP	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	similar	_	_	JJ	_	_	_	_	_
14	safety	_	_	NN	_	_	_	_	_
15	record	_	_	NN	_	_	_	_	_
16	as	_	_	IN	_	_	_	_	_
17	seasonal	_	_	JJ	_	_	_	_	_
18	influenza	_	_	NN	_	_	_	_	_
19	vaccines	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Pandemic	_	_	JJ	_	_	_	_	_
2	influenza	_	_	NN	_	_	_	_	_
3	vaccines	_	_	NNS	_	_	_	_	_
4	underwent	_	_	VBD	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	same	_	_	JJ	_	_	_	_	_
7	production	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	testing	_	_	NN	_	_	_	_	_
10	methods	_	_	NNS	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	seasonal	_	_	JJ	_	_	_	_	_
13	vaccines	_	_	NNS	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	safety	_	_	NN	_	_	_	_	_
3	tracking	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	vaccine	_	_	NN	_	_	_	_	_
7	for	_	_	IN	_	_	_	_	_
8	adverse	_	_	JJ	_	_	_	_	_
9	events	_	_	NNS	_	_	_	_	_
10	after	_	_	IN	_	_	_	_	_
11	its	_	_	PRP$	_	_	_	_	_
12	distribution	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	use	_	_	NN	_	_	_	_	_
15	worldwide	_	_	RB	_	_	_	_	_
16	has	_	_	VBZ	_	_	_	_	_
17	likely	_	_	RB	_	_	_	_	_
18	been	_	_	VBN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	most	_	_	RBS	_	_	_	_	_
21	thorough	_	_	JJ	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	sensitive	_	_	JJ	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	history	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Influenza	_	_	NN	_	_	_	_	_
2	vaccines	_	_	NNS	_	_	_	_	_
3	cause	_	_	VBP	_	_	_	_	_
4	antibodies	_	_	NNS	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	develop	_	_	VB	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	body	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	antibodies	_	_	NNS	_	_	_	_	_
3	provide	_	_	VBP	_	_	_	_	_
4	protection	_	_	NN	_	_	_	_	_
5	against	_	_	IN	_	_	_	_	_
6	infection	_	_	NN	_	_	_	_	_
7	with	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	viruses	_	_	NNS	_	_	_	_	_
10	that	_	_	WDT	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	vaccine	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Possible	_	_	JJ	_	_	_	_	_
2	side	_	_	NN	_	_	_	_	_
3	effects	_	_	NNS	_	_	_	_	_
4	can	_	_	MD	_	_	_	_	_
5	depend	_	_	VB	_	_	_	_	_
6	on	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	type	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	vaccine	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	how	_	_	WRB	_	_	_	_	_
13	it	_	_	PRP	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	administered	_	_	VBN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	age	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	recipient	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	two	_	_	CD	_	_	_	_	_
4	main	_	_	JJ	_	_	_	_	_
5	types	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	vaccines	_	_	NNS	_	_	_	_	_
8	:	_	_	:	_	_	_	_	_
9	one	_	_	CD	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	manufactured	_	_	VBN	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	inactivated	_	_	VBN	_	_	_	_	_
14	viruses	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	other	_	_	JJ	_	_	_	_	_
18	uses	_	_	VBZ	_	_	_	_	_
19	live	_	_	JJ	_	_	_	_	_
20	viruses	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Inactivated	_	_	VBN	_	_	_	_	_
2	vaccines	_	_	NNS	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	administered	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	injection	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	commonly	_	_	RB	_	_	_	_	_
9	cause	_	_	VBP	_	_	_	_	_
10	local	_	_	JJ	_	_	_	_	_
11	reactions	_	_	NNS	_	_	_	_	_
12	such	_	_	JJ	_	_	_	_	_
13	as	_	_	IN	_	_	_	_	_
14	soreness	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	swelling	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	redness	_	_	NN	_	_	_	_	_
19	at	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	injection	_	_	NN	_	_	_	_	_
22	site	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	less	_	_	RBR	_	_	_	_	_
26	often	_	_	RB	_	_	_	_	_
27	can	_	_	MD	_	_	_	_	_
28	cause	_	_	VB	_	_	_	_	_
29	fever	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	muscle-	_	_	NN	_	_	_	_	_
32	or	_	_	CC	_	_	_	_	_
33	joint-	_	_	NN	_	_	_	_	_
34	aches	_	_	NNS	_	_	_	_	_
35	or	_	_	CC	_	_	_	_	_
36	headache	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	symptoms	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	generally	_	_	RB	_	_	_	_	_
5	mild	_	_	JJ	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	do	_	_	VBP	_	_	_	_	_
8	not	_	_	RB	_	_	_	_	_
9	need	_	_	VB	_	_	_	_	_
10	medical	_	_	JJ	_	_	_	_	_
11	attention	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	last	_	_	JJ	_	_	_	_	_
15	1	_	_	CD	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	2	_	_	CD	_	_	_	_	_
18	days	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Fever	_	_	NN	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	aches	_	_	NNS	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	headaches	_	_	NNS	_	_	_	_	_
6	can	_	_	MD	_	_	_	_	_
7	occur	_	_	VB	_	_	_	_	_
8	more	_	_	RBR	_	_	_	_	_
9	frequently	_	_	RB	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	children	_	_	NNS	_	_	_	_	_
12	compared	_	_	VBN	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	elderly	_	_	JJ	_	_	_	_	_
15	people	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_

